Document is current
Any future updates will be listed below
-
Authors
Kowash, Ryan R
Sabnani, Manoj
Gray, Laura T
Deng, Qing
Saleh, Nusrat U A
Girard, Luc
Naito, Yujiro
Masahiro, Kentaro
Minna, John D
Gerber, David E https://orcid.org/0000-0002-7812-6741
Koyama, Shohei https://orcid.org/0000-0002-6897-9417
Liu, Zhiqian Lucy
Baruah, Hemanta
Akbay, Esra A https://orcid.org/0000-0002-4149-2529
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05117476 at ClinicalTrials.govnct06328673 at ClinicalTrials.govDocuments that mention this clinical trial
CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
https://doi.org/10.1136/jitc-2024-008987
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer models
https://doi.org/10.1136/jitc-2024-009867
1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity
https://doi.org/10.1136/jitc-2022-sitc2022.1395
Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.2588
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.2532
195 Pharmacodynamic activities of the anti-MICA/B monoclonal antibody CLN-619, evaluated as a monotherapy, support the proposed mechanisms of action and correlate with response
https://doi.org/10.1136/jitc-2024-sitc2024.0195
194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial
https://doi.org/10.1136/jitc-2023-sitc2023.0194
Documents that mention this clinical trial
Novel and potent MICA/B antibody is therapeutically effective in <i>KRAS LKB1</i> mutant lung cancer models
https://doi.org/10.1136/jitc-2024-009867
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (DP240248)
Cancer Prevention and Research Institute of Texas (RR160080)
National Cancer Center Network (YIA2021)
National Institutes of Health (5P50CA070907)
National Institutes of Health (P30CA142543)
National Institutes of Health (R01CA276058)
National Institutes of Health (R01CA289500)
National Institutes of Health (T32CA124334)
Congressionally Directed Medical Research Programs (W81XWH-21-1-0856)
- License Information
